Stocks · Health care · Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

ESLA Clue Score19

United States Fiscal year ends December CIK 0001844417

$0.41 -1.80% Close, 9 Oct 2026

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.41 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$13.06M

Free cash flow

$1.79M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
7 Oct 2025	Xu Jiandong Chief Financial Officer	Bought	$1.33K	0.4%
22 Sep 2025	Xu Jiandong Chief Financial Officer	Bought	$1.16K	6.4%
11 Sep 2025	Xu Jiandong Chief Financial Officer	Bought	$104.00	0.0%
4 Mar 2022	Li Jianwei Co-Chief Executive Officer	Bought	$44.68B	12.8%

19out of 100

Profitability 0

Financial strength 10

Growth n/a

Insiders 60

Strongest on insiders (60), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan